# Debate Matchup Judgment Report

**Grok 4.6 (high)** vs **Qwen 3.8 Max**

- Paired result: **Tie**
- Mean entertainment: `7.50 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Countries should permit advance market commitments for new antibiotics even if unit prices remain high.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0527__grok-4.6-high__qwen3.8-max__s0__tpl_placement_active_20260813a.md): PRO = **Grok 4.6 (high)**, CON = **Qwen 3.8 Max**
- [Debate B transcript](../../../transcripts/prop_0527__qwen3.8-max__grok-4.6-high__s1__tpl_placement_active_20260813a.md): PRO = **Qwen 3.8 Max**, CON = **Grok 4.6 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0527__grok-4.6-high__qwen3.8-max__s0__tpl_placement_active_20260813a.md)
- Roles: PRO = **Grok 4.6 (high)**, CON = **Qwen 3.8 Max**
- Judged result: Unanimous `3-0` for **Grok 4.6 (high)**.
- Entertainment scores: `7`, `8`, `8`
- Mean signed raw margin (PRO+): `+1.37`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 5 (high) | A = Qwen 3.8 Max (CON); B = Grok 4.6 (high) (PRO) | Grok 4.6 (high) | +1.5 | +1.46 | 7.0 |
| GPT-5.6 Sol (high) | A = Qwen 3.8 Max (CON); B = Grok 4.6 (high) (PRO) | Grok 4.6 (high) | +1.4 | +1.32 | 8.0 |
| Kimi K2.6 | A = Qwen 3.8 Max (CON); B = Grok 4.6 (high) (PRO) | Grok 4.6 (high) | +1.2 | +1.36 | 8.0 |

### Judge Notes

- **Claude Sonnet 5 (high)** (A = Qwen 3.8 Max (CON); B = Grok 4.6 (high) (PRO)): Both sides built coherent cases, but B's economic story was more consistent and better defended under pressure. B's key move—labeling subscriptions/prizes as "hidden AMCs" that face the same underlying arithmetic—forced A to assert rather than fully demonstrate that delinked rewards escape the financing constraint, and A never cleanly rebutted this. B also implicitly modeled AMC mechanics more accurately (government absorbs the high price to secure supply; contract clauses handle allocation), which undercuts A's repeated "tollbooth at the bedside" framing that assumes hospitals/patients directly bear the high unit price—a point B gestured toward (pre-positioned formulary supply) but never fully crystallized, leaving some ambiguity, though the edge still favors B's more grounded picture. A's central weapon was the "redundant-or-harmful" fork on conservation clauses, which was a sharp analytical device, but B's answer (price funds scarcity-matched finance; clauses handle allocation, a separate function) substantially blunted it by decoupling the two jobs rather than conflating them. A's closing "pay before the patient arrives" line was rhetorically strong, but rests on a contestable premise about how AMC pricing reaches the point of care that B had already implicitly challenged. Overall B answered pressure more directly, sustained a tighter causal story, and closed with a cleaner crystallization of the stakes, giving it a clear but not dominant edge.
  Most decisive rebuttal noted: B's "hidden AMC" rebuttal to A's alternative-tools proposal (subscriptions/prizes still require the same total transfer, just relabeled) was the most damaging exchange, since A never fully explained why delinked lump-sum payments escape the same financing arithmetic without political vulnerability, weakening A's core "better tools exist" pillar.
- **GPT-5.6 Sol (high)** (A = Qwen 3.8 Max (CON); B = Grok 4.6 (high) (PRO)): Side B won by exploiting the proposition’s permissive wording and showing that high unit prices can finance deliberately low-volume drugs without excluding access clauses, volume caps, or alternative funding tools. Side A’s delinkage fork was sharp, but listing preferable mechanisms did not justify forbidding a high-price commitment when those alternatives may not produce a drug. B therefore retained the stronger comparison: managed budget pressure on an existing antibiotic is preferable to rationing by total absence.
  Most decisive rebuttal noted: Side B’s answer to the delinkage argument was decisive: subscriptions and prizes may shift the same total payment into a lump sum, but their availability does not establish that countries should veto an otherwise workable AMC. This directly weakened Side A’s false-choice objection and returned the debate to permission rather than exclusive policy design.
- **Kimi K2.6** (A = Qwen 3.8 Max (CON); B = Grok 4.6 (high) (PRO)): PRO successfully defended that high unit prices reflect the economic reality of tiny volumes for last-line antibiotics and that conservation clauses serve a different function (allocation) than price (financing). CON's elegant "fork"—that high prices are either unnecessary or harmful—was directly answered by showing the price is necessary revenue, not monopoly fat, and that banning the tool because theoretically superior alternatives exist ignores the risk of having no drugs at all. PRO's closing crystallized the choice as permission for a viable contract versus a veto based on sticker shock, while CON never fully overcame the comparative harm of missing drugs versus budget reviews. The exchange was competitive but PRO maintained the cleaner path to victory after the full exchange.
  Most decisive rebuttal noted: PRO's answer to CON's fork in Rebuttal 2 [B4.1]: the high unit price finances a tiny-volume product that conservation clauses alone cannot subsidize, while simultaneously acting as a backstop against overuse—showing the price and clause serve distinct, non-redundant functions.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0527__qwen3.8-max__grok-4.6-high__s1__tpl_placement_active_20260813a.md)
- Roles: PRO = **Qwen 3.8 Max**, CON = **Grok 4.6 (high)**
- Judged result: Split `2-1` for **Qwen 3.8 Max**.
- Entertainment scores: `7`, `7`, `8`
- Mean signed raw margin (PRO+): `+0.83`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 5 (high) | A = Grok 4.6 (high) (CON); B = Qwen 3.8 Max (PRO) | Qwen 3.8 Max | +1.6 | +1.55 | 7.0 |
| GPT-5.6 Sol (high) | A = Grok 4.6 (high) (CON); B = Qwen 3.8 Max (PRO) | Qwen 3.8 Max | +2.3 | +2.17 | 7.0 |
| Kimi K2.6 | A = Grok 4.6 (high) (CON); B = Qwen 3.8 Max (PRO) | Grok 4.6 (high) | -1.4 | -1.59 | 8.0 |

### Judge Notes

- **Claude Sonnet 5 (high)** (A = Grok 4.6 (high) (CON); B = Qwen 3.8 Max (PRO)): Both sides built coherent, well-adapted cases, but PRO's core structure held up better under pressure. PRO's opening flagged from the start that AMCs can carry tiered pricing and access conditions [B1.4], and it consistently developed this into a reward-price/access-price distinction that is plausible and grounded in ordinary policy mechanisms (central purchase, reserves, protocol-based release). CON's sharpest weapon—the closing "word remain" trap, arguing that if access is protected the price isn't really "high"—is rhetorically effective and exposed a genuine tension, but it functions more as a definitional objection than a demonstrated harm, and PRO's design was foreshadowed rather than invented late. CON's proposed alternatives (subscriptions, prizes, public manufacturing) were asserted as superior but never shown to be faster, more durable, or free of analogous access problems, leaving CON's rebuttal to PRO's "additional tools, not substitutes" point [B2.4] underdeveloped. CON's rationing/crowding-out mechanism was real and unanswered in full financial detail, but PRO's mitigation story (central financing, capped volumes, rapid release) was a sufficient practical answer given the debate's evidentiary limits. On balance PRO gave the cleaner, more resolution-aligned path to a verdict.
  Most decisive rebuttal noted: CON's late pivot—"if the effective charge is low, the unit price does not remain high, so PRO has abandoned the motion"—was the most incisive exchange, but PRO's earlier-planted reward/access distinction [B1.4, B4.1] blunted its force by showing the design was not an ad hoc retreat.
- **GPT-5.6 Sol (high)** (A = Grok 4.6 (high) (CON); B = Qwen 3.8 Max (PRO)): Side B won by cleanly separating the high price paid to reward development from the cost faced by clinicians and patients through central purchase and reimbursement. Side A raised legitimate fiscal and access concerns, but repeatedly asserted that protocols necessarily cause bedside delay and that subsidized access means the unit price is no longer high. Those claims did not defeat B's plausible model of pre-purchased stock, standing release rules, and central financing. B also won the toolkit comparison: the motion merely permits AMCs, while A never established why potentially preferable subscriptions or prizes justify refusing this option altogether.
  Most decisive rebuttal noted: Side B's answer to A's pressure questions was decisive: a government can still pay a genuinely high per-course developer price while preventing that price from rationing bedside access. A's response largely relabeled this as delinkage rather than showing the arrangement was impossible or outside the motion.
- **Kimi K2.6** (A = Grok 4.6 (high) (CON); B = Qwen 3.8 Max (PRO)): CON trapped PRO on the text of the motion. PRO defended high unit prices by separating the developer's reward price from the patient's access price, but CON showed that arrangement effectively negates high unit prices at the point of care—transforming the AMC into a delinked subscription model rather than defending the proposition's explicit "even if unit prices remain high" clause. PRO never resolved whether high prices are meaningfully tolerated when they are hidden from users, or whether they remain high and therefore produce the bedside rationing and fiscal crowding CON identified. Because PRO could only avoid CON's access harms by redefining the motion, CON's "same-night indicated use" standard provided the cleaner route to victory.
  Most decisive rebuttal noted: CON's Rebuttal 2 argument that PRO's separation of reward and access prices constituted "delinkage in AMC clothing, not the motion" [A4.3], exposing that PRO could only win by redefining "high unit prices" out of the clinical pathway.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0527`
- Side-swap group ID: `prop_0527__grok-4.6-high__qwen3.8-max__tpl_placement_active_20260813a`
- Raw paired winner: **Tie**
- Mean normalized margin for Grok 4.6 (high): `+0.33`
- Complete side swap: `yes`
- Included in ratings: `yes`
